However, our results showed that such association was observed just among lung cancer (dominant model: OR = 0.82, 95% CI = 0.71–0.96; Asp/His versus Asp/Asp: OR = 0.83, 95% CI = 0.71–0.97; additive model: OR = 0.83, 95% CI = 0.72–0.95) for XPF Arg415Gln and hospital-based studies of other cancer (dominant model: OR = 1.23, 95% CI = 1.02–1.49) for XPG Asp1104His, suggesting that other factors may be modulating the XPG Asp1104His and XPF Arg415Gln polymorphisms functionality. This evidence concerns the gene ERCC4 and lung cancer.